Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

we generated $170.7 million in cash flow from operations and deployed $170.0 million to repurchase 9.2 million shares during 2011.

Looking ahead in 2012ViroPharma is reiterating its guidance for the year 2012 as a convenience to investors.  The following guidance provided by ViroPharma are projections, based upon numerous assumptions, all of which are subject to certain risks and uncertainties.  For a discussion of the risks and uncertainties associated with these forward looking statements, please see the Disclosure Notice below.

For the year 2012, ViroPharma expects the following:

  • Worldwide net product sales are expected to be $600 to $660 million;
  • Net U.S. Cinryze sales are expected to be $310 to $330 million;
  • Net Vancocin sales are expected to be $260 to $310 million; and
  • Research and development (R&D) and selling, general and administrative (SG&A) expenses are expected to be $230 to $260 million.

  • Non-GAAP DisclosuresThe Company is reporting both GAAP net income  and non-GAAP adjusted results for the three and twelve months ended December 31, 2011 and 2010.   Non-GAAP adjusted net income is GAAP net income excluding (1) non-cash interest expense, (2) amortization related intangible assets acquired, (3) stock compensation expenses, and (4) certain non-recurring events. Non-GAAP adjusted diluted net income per share reflects the Non-GAAP adjusted net income, after the incremental effect of applying the "if converted" method of accounting to the senior convertible notes, and the diluted shares used in determining our GAAP diluted net income per share. A reconciliation between GAAP and non-GAAP adjusted measures is provided in the Selected Financial Information – Non-GAAP Financial Measures Reconciliation table included with this release. The Company believes that its presentation of historical non-GAAP financial measure
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... Ind. -- Chemists at Indiana University Bloomington have ... bricks-and-mortar fashion, a development with potential value for ... field-effect transistors and photovoltaic cells. , Their paper, ... Crystalline Solids and 2D Self-Assembled Crystals," has been ... journal of the Royal Society of Chemistry. It ...
    (Date:7/31/2014)... 31, 2014 Rogne Bioscience, a privately-held biotechnology ... , has acquired a licence to anti-inflammatory peptides ... The potent anti-inflammatory activity of the peptides was discovered ... of Oxford,s Sir William Dunn School of ... over $1.5 million in seed financing, is developing a ...
    (Date:7/31/2014)... According to a new market ... Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG ... Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, ... the global electrodes market for medical devices was valued ... to reach a market worth USD 1,451.2 million in ...
    (Date:7/31/2014)... SAN DIEGO, July 31, 2014 ... a leading company using proprietary taste science technologies ... for the food, beverage, and ingredient supply industries, ... 2014.  The Company ended the second quarter with ... "During the past quarter Senomyx ...
    Breaking Biology Technology:Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 2Oxford licenses anti-inflammatory peptides to San Francisco Bay Area start-up 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 2Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 3Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 4Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 5Electrodes for Medical Devices Market Expected to Reach USD 1.45 Billion Globally in 2019: Transparency Market Research 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16
    ... Colo., Nov. 18 HEALTHeCAREERS Network, an,onTargetjobs Inc. ... the,American Society of Radiologic Technologists, (ASRT) Education and ... radiologic technologists (R.T.s) nationwide. , ... ) , ...
    ... and sellers of technology businesses through a confidential listing service. ... buyers and sellers of technology business, with reduced effort and ... ... November 18, 2008 -- TechMandA.com today announced ...
    ... Asia to offer the In-Space percutaneous interspinous distraction device, a revolutionary ... ... -- Singapore,s ParkwayHealth is the first healthcare group in Southeast Asia ... spinal procedure ., , , , ,It is the bane of ...
    Cached Biology Technology:HEALTHeCAREERS Network Pledges $15,000 to ASRT Foundation for Professional Healthcare Training 2HEALTHeCAREERS Network Pledges $15,000 to ASRT Foundation for Professional Healthcare Training 3TechMandA.com Marketplace Streamlines M&A Process for Technology Businesses 2TechMandA.com Marketplace Streamlines M&A Process for Technology Businesses 3Singapore Medicine - Singapore Doctors Use Hi-Tech Implant to Add Space to Narrowed Spinal Canals 2Singapore Medicine - Singapore Doctors Use Hi-Tech Implant to Add Space to Narrowed Spinal Canals 3Singapore Medicine - Singapore Doctors Use Hi-Tech Implant to Add Space to Narrowed Spinal Canals 4
    (Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
    (Date:7/31/2014)... first discovered the photovoltaic effect in 1839, humankind has ... sunlight for its own purposes. In a new research ... FASEB Journal , scientists may have ... sunlight by focusing on a naturally occurring combination of ... conservationor persistence over time and across speciessuggests that this ...
    (Date:7/31/2014)... flowers- they are an iconic symbol of tropical ... the landscape. Some, like Hawaii,s State Flower- ... a relatively few botanists and Hawaiian conservation workers, ... intriguing related group of plants known as ... of Hibiscus species are in fact highly endangered. ...
    Breaking Biology News(10 mins):Scientists shine bright new light on how living things capture energy from the sun 2Brother of Hibiscus is found alive and well on Maui 2
    ... release is available in French . ... the influence of the drug metyrapone reduces the brain,s ability ... University of Montreal researchers at the Centre for Studies on ... the theory that memories cannot be modified once they are ...
    ... board feet of softwood logs and 224.9 million board feet ... and Alaska in January, February, and March of this year, ... Station. "The volume of softwood log exports was up ... quarter of 2010, while the volume of softwood lumber exports ...
    ... 40 years, the International Union for Conservation of Nature (IUCN) ... conservation status of various species of animals. They are now ... present is dramatic. According to recent estimates, around 20 per ... though the exact number is unknown since such a ...
    Cached Biology News:Drug may help overwrite bad memories 2West coast's log, lumber exports increase in first quarter of 2011 2West coast's log, lumber exports increase in first quarter of 2011 3Rethinking extinction 2
    ... Kit Components , 25 g Blocking Reagent , ... 10 ml T7 Elution Buffer , 0.2 ml BL21 ... 0.2 ml BLT5615 glycerol stock , 1010 pfu ... Control Lysate , 50 l S-protein HRP Conjugate , ...
    ... WesternBreeze Immunodetection Kits are designed for ... on nitrocellulose or PVDF membranes. Since ... membranes and primary antibodies), the WesternBreeze ... optimizing your protocol and getting your ...
    ... Monoclonal to L1 Cell Adhesion Molecule ... located in Xq28, is involved in three ... aqueduct of Sylvius); 2) MASA (mental retardation, ... SPG1 (spastic paraplegia). Immunogen: ...
    Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Biology Products: